Introduction

The LeQtradose technology is expected to enable the creation of a wide range of unique, patent-protected, drug delivery systems, offering pharmaceutical companies a number of proprietary solutions to currently unmet market needs.

About the Company

Phoqus was established in 1997 as a spin-off from Colorcon, the world's leading supplier of coating materials to the pharmaceutical industry, with a mission to develop and commercialise, using venture capital financing, a range of novel drug delivery systems created from the application of a novel proprietary electrostatic powder deposition technology to pharmaceutical dosage forms. Initial venture capital funding was provided by Advent Venture Partners and 3i plc.

The company has office, laboratory and a cGMP plant on a business park location in West Malling, near Maidstone, Kent.

Phoqus has an experienced management team and is currently expanding its technical operations in order to address the challenge of developing the extensive range of potential opportunities in the drug delivery market. The company has a number of alliances with companies that provide specific expertise in areas critical to the successful development of the LeQtradose technology.

About the Technology